Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2016

Publication ID: GMD0416009
Publication Date: April 20, 2016
Pages: 607
Publisher: Global Markets Direct
Countries: Global [1]

$2,000.00

Publication Type *
- Select -

Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.

Add to cart

Diseases [2]
Pharma & Healthcare [3]
Description:

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2016’, provides an overview of the Chronic Obstructive Pulmonary Disease (COPD) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chronic Obstructive Pulmonary Disease (COPD)
- The report reviews pipeline therapeutics for Chronic Obstructive Pulmonary Disease (COPD) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.

The report reviews key players involved Chronic Obstructive Pulmonary Disease (COPD) therapeutics and enlist all their major and minor projects.

The report assesses Chronic Obstructive Pulmonary Disease (COPD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The report summarizes all the dormant and discontinued pipeline projects.

The report reviews latest news related to pipeline therapeutics for Chronic Obstructive Pulmonary Disease (COPD).

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (COPD) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents:

Table of Contents
Table of Contents 2
Introduction 7
Chronic Obstructive Pulmonary Disease (COPD) Overview 8
Therapeutics Development 9
Chronic Obstructive Pulmonary Disease (COPD) – Therapeutics under Development by Companies 11
Chronic Obstructive Pulmonary Disease (COPD) – Therapeutics under Investigation by Universities/Institutes 21
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline Products Glance 22
Chronic Obstructive Pulmonary Disease (COPD) – Products under Development by Companies 26
Chronic Obstructive Pulmonary Disease (COPD) – Products under Investigation by Universities/Institutes 40
Chronic Obstructive Pulmonary Disease (COPD) – Companies Involved in Therapeutics Development 41
Chronic Obstructive Pulmonary Disease (COPD) – Therapeutics Assessment 150
Drug Profiles 170
Chronic Obstructive Pulmonary Disease (COPD) – Recent Pipeline Updates 449
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects 546
Chronic Obstructive Pulmonary Disease (COPD) – Discontinued Products 568
Chronic Obstructive Pulmonary Disease (COPD) – Product Development Milestones 574
Appendix 583

List of Tables
Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H1 2016 32
Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD) – Comparative Analysis, H1 2016 33
Number of Products under Development by Companies, H1 2016 35
Number of Products under Development by Companies, H1 2016 (Contd..1) 36
Number of Products under Development by Companies, H1 2016 (Contd..2) 37
Number of Products under Development by Companies, H1 2016 (Contd..3) 38
Number of Products under Development by Companies, H1 2016 (Contd..4) 39
Number of Products under Development by Companies, H1 2016 (Contd..5) 40
Number of Products under Development by Companies, H1 2016 (Contd..6) 41
Number of Products under Development by Companies, H1 2016 (Contd..7) 42
Number of Products under Development by Companies, H1 2016 (Contd..8) 43
Number of Products under Investigation by Universities/Institutes, H1 2016 44
Comparative Analysis by Late Stage Development, H1 2016 45
Comparative Analysis by Clinical Stage Development, H1 2016 46
Comparative Analysis by Early Stage Development, H1 2016 47
Comparative Analysis by Unknown Stage Development, H1 2016 48
Products under Development by Companies, H1 2016 49
Products under Development by Companies, H1 2016 (Contd..1) 50
Products under Development by Companies, H1 2016 (Contd..2) 51
Products under Development by Companies, H1 2016 (Contd..3) 52
Products under Development by Companies, H1 2016 (Contd..4) 53
Products under Development by Companies, H1 2016 (Contd..5) 54
Products under Development by Companies, H1 2016 (Contd..6) 55
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by AB2 Bio Ltd., H1 2016
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Abeona Therapeutics, Inc., H1 2016
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2016
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Achillion Pharmaceuticals, Inc., H1 2016
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Adamis Pharmaceuticals Corporation, H1 2016
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Advinus Therapeutics Ltd., H1 2016
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Alchemia Limited, H1 2016
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by AlgiPharma AS, H1 2016
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Allinky Biopharma, H1 2016
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Amakem NV, H1 2016
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Ampio Pharmaceuticals, Inc., H1 2016
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Angion Biomedica Corp., H1 2016
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Apellis Pharmaceuticals, Inc., H1 2016
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Aridis Pharmaceuticals LLC, H1 2016
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Ario Pharma Ltd, H1 2016
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Astellas Pharma Inc., H1 2016
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by AstraZeneca Plc, H1 2016
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Asubio Pharma Co., Ltd., H1 2016
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Axikin Pharmaceuticals, Inc., H1 2016
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Beech Tree Labs, Inc., H1 2016
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Bioneer Corporation, H1 2016
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Biotie Therapies Corp., H1 2016
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Boehringer Ingelheim GmbH, H1 2016
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by C4X Discovery Holdings PLC, H1 2016
88
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Carolus Therapeutics, Inc., H1 2016 89
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Cellular Biomedicine Group, Inc., H1
2016 90
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Chiesi Farmaceutici SpA, H1 2016 91
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Circassia Pharmaceuticals Plc, H1
2016 92
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by CSL Limited, H1 2016 93
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Cytokinetics, Inc., H1 2016 94
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Daiichi Sankyo Company, Limited, H1
2016 95
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Domainex Limited, H1 2016 96
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Dong Wha Pharma Co., Ltd., H1 2016
97
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Elsalys Biotech SAS, H1 2016 98
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by enGene, Inc, H1 2016 99
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Errant Gene Therapeutics, LLC, H1
2016 100
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
101
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Five Prime Therapeutics, Inc., H1 2016
102
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Foresee Pharmaceuticals, LLC, H1
2016 103
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Galapagos NV, H1 2016 104
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Gilead Sciences, Inc., H1 2016 105
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by GlaxoSmithKline Plc, H1 2016 106
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1
2016 107
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by iCeutica, Inc., H1 2016 108
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by InMed Pharmaceuticals Inc., H1 2016
109
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Innate Pharma S.A., H1 2016 110
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by INVENT Pharmaceuticals, Inc., H1 2016
111
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Invion Limited, H1 2016 112
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Jiangsu Hansoh Pharmaceutical Co.,
Ltd., H1 2016 113
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Johnson & Johnson, H1 2016 114
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by KaloBios Pharmaceuticals, Inc., H1 2016 115
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2016 116
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016 117
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Ligand Pharmaceuticals, Inc., H1 2016 118
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Medestea Research & Production S.p.A., H1 2016 119
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Merck & Co., Inc., H1 2016 120
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Mereo Biopharma Group Limited, H1 2016 121
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Microbion Corporation, H1 2016 122
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Nivalis Therapeutics, Inc., H1 2016 123
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Nostrum Pharmaceuticals, LLC, H1 2016 124
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Novabiotics Limited, H1 2016 125
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Novartis AG, H1 2016 126
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Odan Laboratories Ltd., H1 2016 127
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by OPKO Health, Inc., H1 2016 128
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Orion Oyj, H1 2016 129
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Otsuka Holdings Co., Ltd., H1 2016 130
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Panmira Pharmaceuticals, LLC., H1 2016 131
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Peptinnovate Limited, H1 2016 132
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Pfizer Inc., H1 2016 133
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by PharmaLundensis AB, H1 2016 134
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Pharmaxis Limited, H1 2016 135
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Polyphor Ltd., H1 2016 136
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Promedior, Inc., H1 2016 137
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by ProMetic Life Sciences Inc., H1 2016 138
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Proteostasis Therapeutics, Inc., H1 2016 139
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Pulmagen Therapeutics LLP, H1 2016 140
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Pulmatrix, Inc., H1 2016 141
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Quark Pharmaceuticals, Inc., H1 2016 142
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Re-Pharm Limited, H1 2016 143
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Recipharm AB, H1 2016 144
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Respira Therapeutics, Inc., H1 2016 145
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Respiratorius AB, H1 2016 146
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by rEVO Biologics, Inc., H1 2016 147
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Rhizen Pharmaceuticals S.A., H1 2016 148
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Seoul Pharma Co., Ltd., H1 2016 149
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Skypharma Plc, H1 2016 150
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Spring Bank Pharmaceuticals, Inc., H1 2016 151
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Stelic Institute & Co., Inc., H1 2016 152
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Sterna Biologicals GmbH & Co KG, H1 2016 153
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Sucampo Pharmaceuticals, Inc., H1 2016 154
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2016 155
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Sunovion Pharmaceuticals Inc., H1 2016 156
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Synovo GmbH, H1 2016 157
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Syntrix Biosystems, Inc., H1 2016 158
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 159
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016 160
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Therabron Therapeutics, Inc., H1 2016 161
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Theraclone Sciences, Inc., H1 2016 162
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Theravance Biopharma, Inc., H1 2016 163
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Torrent Pharmaceuticals Limited, H1 2016 164
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Unizyme Laboratories A/S, H1 2016 165
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Vectura Group Plc, H1 2016 166
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Verona Pharma Plc, H1 2016 167
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Vertex Pharmaceuticals Incorporated, H1 2016 168
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by vTv Therapeutics LLC, H1 2016 169
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Yuhan Corporation, H1 2016 170
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Yungjin Pharm. Co., Ltd., H1 2016 171
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Zambon Company S.p.A., H1 2016 172
Assessment by Monotherapy Products, H1 2016 173
Assessment by Combination Products, H1 2016 174
Number of Products by Stage and Target, H1 2016 176
Number of Products by Stage and Mechanism of Action, H1 2016 183
Number of Products by Stage and Route of Administration, H1 2016 190
Number of Products by Stage and Molecule Type, H1 2016 192
Chronic Obstructive Pulmonary Disease (COPD) Therapeutics – Recent Pipeline Updates, H1 2016 192
Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects, H1 2016 569
Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects (Contd..1), H1 2016 570
Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects (Contd..2), H1 2016 571
Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects (Contd..3), H1 2016 572
Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects (Contd..4), H1 2016 573
Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects (Contd..5), H1 2016 574
Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects (Contd..6), H1 2016 575
Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects (Contd..7), H1 2016 576
Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects (Contd..8), H1 2016 577
Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects (Contd..9), H1 2016 578
Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects (Contd..10), H1 2016 579
Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects (Contd..11), H1 2016 580
Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects (Contd..12), H1 2016 581
Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects (Contd..13), H1 2016 582
Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects (Contd..14), H1 2016 583
Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects (Contd..15), H1 2016 584
Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects (Contd..16), H1 2016 585
Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects (Contd..17), H1 2016 586
Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects (Contd..18), H1 2016 587
Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects (Contd..19), H1 2016 588
Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects (Contd..20), H1 2016 589
Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects (Contd..21), H1 2016 590
Chronic Obstructive Pulmonary Disease (COPD) – Discontinued Products, H1 2016 591
Chronic Obstructive Pulmonary Disease (COPD) – Discontinued Products (Contd..1), H1 2016 592
List of Figures

Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H1 2016 32
Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD) – Comparative Analysis, H1 2016 33
Number of Products under Development by Companies, H1 2016 34
Number of Products under Investigation by Universities/Institutes, H1 2016 44
Comparative Analysis by Late Stage Development, H1 2016 45
Comparative Analysis by Clinical Stage Development, H1 2016 46
Comparative Analysis by Early Stage Products, H1 2016 47
Assessment by Monotherapy Products, H1 2016 173
Assessment by Combination Products, H1 2016 174
Number of Products by Top 10 Targets, H1 2016 175
Number of Products by Stage and Top 10 Targets, H1 2016 175
Number of Products by Top 10 Mechanism of Actions, H1 2016 182
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 182
Number of Products by Top 10 Routes of Administration, H1 2016 189
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 189
Number of Products by Top 10 Molecule Types, H1 2016 191
Number of Products by Stage and Top 10 Molecule Types, H1 2016 191

Companies Mentioned:

AB2 Bio Ltd.
Abeona Therapeutics, Inc.
Ache Laboratorios Farmaceuticos S/A
Achillion Pharmaceuticals, Inc.
Adamis Pharmaceuticals Corporation
Advinus Therapeutics Ltd.
Alchemia Limited
AlgiPharma AS
Allinky Biopharma
Amakem NV
Ampio Pharmaceuticals, Inc.
Angion Biomedica Corp.
Apellis Pharmaceuticals, Inc.
Aridis Pharmaceuticals LLC
Ario Pharma Ltd
Astellas Pharma Inc.
AstraZeneca Plc
Asubio Pharma Co., Ltd.
Axikin Pharmaceuticals, Inc.
Beech Tree Labs, Inc.
Bioneer Corporation
Biotie Therapies Corp.
Boehringer Ingelheim GmbH
C4X Discovery Holdings PLC
Carolus Therapeutics, Inc.
Cellular Biomedicine Group, Inc.
Chiesi Farmaceutici SpA
Circassia Pharmaceuticals Plc
CSL Limited
Cytokinetics, Inc.
Daiichi Sankyo Company, Limited
Domainex Limited
Dong Wha Pharma Co., Ltd.
Elsalys Biotech SAS
enGene, Inc
Errant Gene Therapeutics, LLC
F. Hoffmann-La Roche Ltd.
Five Prime Therapeutics, Inc.
Foresee Pharmaceuticals, LLC
Galapagos NV
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Hanmi Pharmaceuticals, Co. Ltd.
iCeutica, Inc.
InMed Pharmaceuticals Inc.
Innate Pharma S.A.
INVENT Pharmaceuticals, Inc.
Invion Limited
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Johnson & Johnson
KaloBios Pharmaceuticals, Inc.
Kissei Pharmaceutical Co., Ltd.
Kyowa Hakko Kirin Co., Ltd.
Syntrix Biosystems, Inc.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.
Therabron Therapeutics, Inc.
Theraclone Sciences, Inc.
Theravance Biopharma, Inc.
Torrent Pharmaceuticals Limited
Unizyme Laboratories A/S
Vectura Group Plc
Verona Pharma Plc
Vertex Pharmaceuticals Incorporated
vTv Therapeutics LLC
Yuhan Corporation
Yungjin Pharm. Co., Ltd.
Zambon Company S.p.A.

License Types:

**Single User License (PDF)**
- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Global License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

**Site License (PDF)**
- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Global License is purchased, a Site User License must be purchased for every corporate
location by an organization that wishes to use the publication within the same organization.

- Customers who infringe these license terms are liable for a Global license fee.

**Global License (PDF)**

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

---

**Source URL:** https://www.marketresearchreports.com/global-markets-direct/chronic-obstructive-pulmonary-disease-copd-pipeline-review-h1-2016

**Links**